Phase 1 dose escalation study of copanlisib (BAY 80-6946) in combination with gemcitabine or gemcitabine-cisplatin in advanced cancer patients.

2610 Background: Copanlisib (BAY 80–6946) is a potent and reversible pan-class I PI3K inhibitor with significant activity against PI3K-δ and PI3K-α isoforms. We report the results of an open-label,...